ToledoLab_VHIO
@rtoledolab
🗞 Publicados en Nature Medicine los resultados de un estudio liderado por @elena_elez y Rodrigo A. Toledo que identifican un biomarcador de respuesta al tratamiento para el #cáncercolorrectal metastásico BRAF-V600E ➕ bit.ly/VHIO-BRAFV600E…
🗞 Published in Nature Medicine results of study led by VHIO’s @elena_elez and Rodrigo A. Toledo unveil a biomarker of response to therapy in pts with microsatellite stable, BRAFV 600E mutated #metastaticcolorectalcancer ➕ bit.ly/VHIO-BRAFV600E
#Pacientes | Investigadores de Vall d’Hebron Institute of Oncology (VHIO) descubren mutaciones en un gen que podría ayudar a seleccionar aquellos pacientes que responden al tratamiento para un #cáncer colorrectal metastásico consalud.es/pacientes/paci…
🔔Today is THE DAY! Kick-off meeting del proyecto con sesión inaugural a cargo del IP de proyecto Enrique de Álava.
📢Hoy, el Dr. Enrique de Álava, coordinador del proyecto #Immune4ALL nos cuenta cuál es el objetivo principal del proyecto y qué resultados en salud se pretenden alcanzar. 🎯 CIBER ISCIII CIBERONC CIBERehd CIBERER CIBER-BBN
Harnessing clonal evolution of pancreatic cancer using longitudinal WES-ctDNA. Fantastic collaboration with Nicholas McGranahan Ariana Huebner James Black Manuel Hidalgo 🇪🇸 🇺🇸 #PancreaticCancer #ctDNA genomemedicine.biomedcentral.com/articles/10.11…
Glad to share our new publication on PDAC evolution using ACT-Discover ToledoLab_VHIO, Manuel Hidalgo 🇪🇸 🇺🇸, and Nicholas McGranahan Vall d’Hebron Institute of Oncology (VHIO)
🚨The Vall d’Hebron Institute of #Oncology Vall d’Hebron Institute of Oncology (VHIO) has an #openposition for a Junior Group Leader keen to launch a #research lab in #hematooncology & #Immunotherapy Check here and reach out if you have questions! 👉🏽vhio.net/2023/05/12/ref… #CARTcell #Immunology #CancerResearch
Fantastic work by Igor Adameyko on characterizing embryological development of chromaffin cells using #scRNAseq ECE2023 - XII European Congress of Entomology European Network for the Study of Adrenal Tumours
Published in Genome Medicine, a study co-led by VHIO’s Rodrigo A. Toledo reports on the development of new liquid biopsy methodology that showed 30% increased sensitivity in detecting ctDNA in pts with #AdvancedPancreaticCancer. ➕ bit.ly/ACT-DiscoverVH…
Enhorabuena‼️ ToledoLab_VHIO recibe una de las Ayudas para la Investigación de la Asociación PHEiPAS para investigar la utilidad de la biopsia líquida en un grupo de tumores raros. ➕ bit.ly/RToledoPHEiPAS…
Predictive Impact of mRNF43 in MSS mBRAFV600E mCRC Treated With Target Therapy or CTx JCO Precision Oncology doi.org/10.1200/PO.23.… 👉pMMR/MSS mBRAFV600E mCRC benefit from TT vs CT independently of RNF43 mutational 👉Nevertheless, intersting efficacy in mRNF43 pts... ESMO - Eur. Oncology OncoAlert
Now online in Cancer Discovery: Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes - by Carlota Arenillas, ToledoLab_VHIO, and colleagues doi.org/10.1158/2159-8… Vall d’Hebron Institute of Oncology (VHIO)
New paper from our Lab out in Cancer Discovery Cancer Discovery ! aacrjournals.org/cancerdiscover…
I also had the rare (and fun) opportunity to tell an author their work was going to be on the cover of an upcoming issue when I met ToledoLab_VHIO at #AACR25! 😊
Featured on the cover: Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes brnw.ch/21wSxEo By Carlota Arenillas, ToledoLab_VHIO, and colleagues Vall d’Hebron Institute of Oncology (VHIO)
